Search Technologies
Displaying 41 - 50 of 225 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
KCNMA1-H444Q
Published Monday, May 1, 2023KCNMA1-H444Q knock-in mice express a loss-of-function (LOF) histidine to glutamine substitution at position 444 of the potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA) gene. Mice exhibit locomotor dysfunction and hyperactive dyskinesia. These mice may be useful for studying paroxysmal...
Investigator(s): Andrea Meredith
Docket: AM-2019-105
-
KCNMA1-D434G Transgenic Mouse Line
Published Thursday, April 27, 2023KCNMA1-D434G knock-in mice express a gain-of-function (GOF) autosomal dominant aspartic acid to glycine substitution at position 434 of the potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (...
Investigator(s): Andrea Meredith
Categories: Research Tools, Antibodies, & Reagents, Genetics
Docket: AM-2019-104
-
Kcnma1fl-tdTomato Conditional Knockout Mice
Published Monday, January 9, 2023Kcnma1fl-tdTomato conditional mutant mice possess loxP sites flanking exon 2 and a tdTomato reporter (that only expresses upon cre-recombination) in the Kcnma1 (potassium large conductance calcium-activated channel, subfamily M, alpha member 1) gene and may be useful in generating conditional mutations to study the function of BK currents...
Investigator(s): Andrea Meredith
Categories: Research Tools, Antibodies, & Reagents
Keyword(s): Molecular Biology; Neuroscience; Genetics; Transgenic mice
Docket: AM-2013-078
-
BLEEDING RISK INDEX (BRI) PREDICTION ALGORITHM
Published Monday, November 7, 2022Hemorrhage is the most common cause of preventable death on the battlefield and in civilian trauma care. Triaging patients that may have life-threatening bleeding in the field is essential for distinguishing those who need trauma center care, early control of bleeding, and blood transfusion. The UMB inventors developed the Bleeding Risk Index (...
Investigator(s): Peter Hu, Colin Mackenzie, Shiming Yang, Hegang Chen, Konstantinos Kalpakis
Categories: Software + Algorithm, Healthcare
Keyword(s): Clinical decision support; blood transfusion; triage
Docket: PH-2014-007; PH-2016-074
-
Real-Time Critical-Care Patient Vital Signs Viewer System
Published Monday, November 7, 2022Our team of trauma care specialists at University of Maryland, Baltimore built the “Real-Time Critical-Care Patient Vital Signs Viewer System” (the “VS Viewer”) as a custom-designed physiological data display system that allows for bedside and remote monitoring of critically ill patients. In fact, the system has reliably been running...
Investigator(s): Peter Hu, Shiming Yang, Colin Mackenzie, Thomas Scalea, Lynn Stansbury, Deborah Stein
Categories: Software + Algorithm, Healthcare, Sensors/Monitors
Keyword(s): Trauma care; remote monitor; clinical decision support tool
Docket: PH-2012-076
-
Novel Ketamine Metabolites for Treating Depression, Anxiety & Addiction
Published Monday, November 7, 2022UMB inventors from Prof. Todd Gould’s lab, along with their collaborators, made the pivotal discovery in 2016 that certain stable ketamine metabolites exerted antidepressant actions via a different mechanism (independent of NMDAR inhibition), which made these compounds excellent drug candidates, without the negative side effects associated with...
Investigator(s): Todd Gould, Jaclyn Highland, Panos Zanos, Craig Thomas, Patrick Morris
Categories: Therapeutics, Small molecules
Keyword(s): small molecule; ketamine-related; depression; addiction
Docket: TG-2021-015
-
Biofilm Antigen-Based Diagnostic for Chronic Staph aureus Infection
Published Tuesday, August 2, 2022Chronic infections associated with implanted medical devices such as prosthetic joints are difficult to diagnose and treat due to biofilm formation by the causative pathogens. Bacterial infections often persist in the form of protective biofilms (65 - 80% of all infections), a mode of growth which reduces the effectiveness of the host immune...
Investigator(s): Rebecca Brady, Jennifer Kofonow, Timothy Vail, Jeffrey Leid, Janette Harro, & Mark Shirtliff
Categories: Diagnostics
Keyword(s): infection, diagnostic, prosthetic joint infection, Biofilm, Staphylococcus aureus
Docket: MS-2008-064
-
Xv1 Inhibition As A Novel Antimitotic Cancer Therapy
Published Thursday, July 7, 2022Mitosis has been an attractive target for anti-cancer therapies given that uncontrolled cell division is one of the key hallmarks of cancer. However, some normal cells like hematopoietic progenitor cells (HPCs), also undergo rapid cell division. Therefore, nearly all current cell cycle-targeted drugs are limited by their severe toxicity to such...
Investigator(s): Shengyun Fang, Yongwang Zhong
Keyword(s): cancer, Cancer Therapy, Targeted Therapy, XBP1, Xv1
Docket: SF-2020-011
-
LRP1 Antagonists for Treatment and Prevention of Alzheimer’s Disease
Published Thursday, May 26, 2022Alzheimer’s disease (AD) is a neurodegenerative disease characterized by gradual deterioration of the brain cells and loss of multiple cognitive functions. The cognitive decline in AD is closely linked to aggregated forms of tau which form neurofibrillary tangles (“NFT”) that initiate in the entorhinal cortex...
Investigator(s): Dudley Strickland, Molly Migliorini, Brian Hampton, Joana Cooper, Selen Muratoglu Catania, Bradley Hyman, Aurelien Lathuiliere
Categories: Therapeutics, Methods of Treatment
Keyword(s): Alzheimer’s Disease, Therapeutics, LRP1, Tau, Method, CNS
Docket: DS-2020-052
-
NEU1-Selective Sialidase Inhibitors for Treatment of Idiopathic Pulmonary Fibrosis
Published Thursday, May 12, 2022Idiopathic Pulmonary Fibrosis (IPF) is an unrelenting, uniformly fatal disease in which lung architecture is distorted and replaced by scar tissue, thereby compromising pulmonary function. IPF patients only survive 2 to 3 years after diagnosis. Although numerous host factors have been implicated in IPF pathogenesis, no unified mechanistic...
Investigator(s): Simeon Goldblum; Irina Luzina; Sergei Atamas
Categories: Therapeutics, Methods of Treatment
Keyword(s): Fibrosis, Therapeutics, IPF
Docket: SG-2019-090